Kodiak Sciences Shares Climb on Positive Late-Stage Trial Results

Dow Jones03-26 18:55

By Connor Hart

Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs when damaged blood vessels leak blood and fluid into the retina.

The stock jumped 32%, to $29.92, in premarket trading Thursday. Through Wednesday's close, shares have surged more than sevenfold over the past year.

The biotechnology company said before the bell that its treatment, zenkuda, demonstrated superiority compared with placebo. A total of 62.5% of patients treated with the therapy achieved a greater than or equal to 2-step improvement in diabetic retinopathy severity score, compared with 3.3% of sham-treated patients.

Zenkuda also demonstrated superiority to sham in its secondary endpoint, with an 85% risk reduction for the development of a sight-threatening complication, Kodiak said.

Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study, noting it plans to accelerate its biologics license application, or BLA, submission plans as a result.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

March 26, 2026 06:55 ET (10:55 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622859254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 18:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622859254","market":"fut","top_or_hot":-1,"title":"Kodiak Sciences Shares Climb on Positive Late-Stage Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs when damaged blood vessels leak blood and fluid into the retina. \n</p>\n<p>\n  The stock jumped 32%, to $29.92, in premarket trading Thursday. Through Wednesday's close, shares have surged more than sevenfold over the past year. \n</p>\n<p>\n  The biotechnology company said before the bell that its treatment, zenkuda, demonstrated superiority compared with placebo. A total of 62.5% of patients treated with the therapy achieved a greater than or equal to 2-step improvement in diabetic retinopathy severity score, compared with 3.3% of sham-treated patients. \n</p>\n<p>\n  Zenkuda also demonstrated superiority to sham in its secondary endpoint, with an 85% risk reduction for the development of a sight-threatening complication, Kodiak said. \n</p>\n<p>\n  Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study, noting it plans to accelerate its biologics license application, or BLA, submission plans as a result. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2026 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences Shares Climb on Positive Late-Stage Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences Shares Climb on Positive Late-Stage Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-26 18:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs when damaged blood vessels leak blood and fluid into the retina. \n</p>\n<p>\n  The stock jumped 32%, to $29.92, in premarket trading Thursday. Through Wednesday's close, shares have surged more than sevenfold over the past year. \n</p>\n<p>\n  The biotechnology company said before the bell that its treatment, zenkuda, demonstrated superiority compared with placebo. A total of 62.5% of patients treated with the therapy achieved a greater than or equal to 2-step improvement in diabetic retinopathy severity score, compared with 3.3% of sham-treated patients. \n</p>\n<p>\n  Zenkuda also demonstrated superiority to sham in its secondary endpoint, with an 85% risk reduction for the development of a sight-threatening complication, Kodiak said. \n</p>\n<p>\n  Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study, noting it plans to accelerate its biologics license application, or BLA, submission plans as a result. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 26, 2026 06:55 ET (10:55 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622859254","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622859254","pubTimestamp":1774522500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs when damaged blood vessels leak blood and fluid into the retina.The stock jumped 32%, to $29.92, in premarket trading Thursday. Through Wednesday's close, shares have surged more than sevenfold over the past year.The biotechnology company said before the bell that its treatment, zenkuda, demonstrated superiority compared with placebo. A total of 62.5% of patients treated with the therapy achieved a greater than or equal to 2-step improvement in diabetic retinopathy severity score, compared with 3.3% of sham-treated patients.Zenkuda also demonstrated superiority to sham in its secondary endpoint, with an 85% risk reduction for the development of a sight-threatening complication, Kodiak said.Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study, noting it ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技","SSI":"Stage Stores Inc"},"translate_title":"Kodiak Sciences股价因后期试验结果积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9,"SSI":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Kodiak Sciences shot higher after the company disclosed what it called positive results from a late-stage study of its treatment for diabetic retinopathy, a progressive disease that occurs when damaged blood vessels leak blood and fluid into the retina. \n\n\n  The stock jumped 32%, to $29.92, in premarket trading Thursday. Through Wednesday's close, shares have surged more than sevenfold over the past year. \n\n\n  The biotechnology company said before the bell that its treatment, zenkuda, demonstrated superiority compared with placebo. A total of 62.5% of patients treated with the therapy achieved a greater than or equal to 2-step improvement in diabetic retinopathy severity score, compared with 3.3% of sham-treated patients. \n\n\n  Zenkuda also demonstrated superiority to sham in its secondary endpoint, with an 85% risk reduction for the development of a sight-threatening complication, Kodiak said. \n\n\n  Chief Executive Victor Perlroth said the company is encouraged by the outcome of the study, noting it plans to accelerate its biologics license application, or BLA, submission plans as a result. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2026 06:55 ET (10:55 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622859254","isCrawlerRequest":true}